Online citations, reference lists, and bibliographies.
← Back to Search

Declining Morbidity And Mortality Among Patients With Advanced Human Immunodeficiency Virus Infection. HIV Outpatient Study Investigators.

F. Palella, K. Delaney, A. Moorman, M. Loveless, J. Fuhrer, G. Satten, D. Aschman, S. Holmberg
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND AND METHODS National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS). To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997. RESULTS Mortality among the patients declined from 29.4 per 100 person-years in the first quarter of 1995 to 8.8 per 100 in the second quarter of 1997. There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV. The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997. In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality. Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit. Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid. CONCLUSIONS The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
This paper references
Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
Ann Marie Swart (1994)
Implications of generalists' slow adoption of zidovudine in clinical practice.
L. Markson (1994)
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy
J. Coffin (1995)
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
D. Ho (1995)
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
D. Katzenstein (1996)
Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival.
M. Kitahata (1996)
Viral Counts Count in HIV Infection
D. Ho (1996)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.
C. Carpenter (1996)
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
W. O'brien (1996)
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
J. Darbyshire (1996)
HIV viral load markers in clinical practice
M. Saag (1996)
Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
J. Mellors (1996)
Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection
R. D'Aquila (1996)
Lamivudine Plus Zidovudine Compared with Zalcitabine Plus Zidovudine in Patients with HIV Infection
J. Bartlett (1996)
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
S. Hammer (1996)
Decline in deaths from AIDS due to new antiretrovirals
R. Hogg (1997)
Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure
W. O'brien (1997)
Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection
J. Mellors (1997)
Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response
M. Hughes (1997)
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
S. Hammer (1997)
Impact of combination therapy for HIV infection on inpatient census.
R. A. Torres (1997)

This paper is referenced by
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
J. Frater (2021)
2021 European Guideline on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens
H. D. de Vries (2021)
Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier
B. Boyarsky (2021)
Emergency Department Utilization Among People Living With HIV on Chronic Opioid Therapy
K. Thakarar (2021)
Missed opportunities for HIV testing in patients newly diagnosed with HIV in Morocco
L. Marih (2021)
Modeling within-host viral dynamics: The role of CTL immune responses in the evolution of drug resistance
Q. Deng (2021)
Secular Trends in Breast Cancer Risk among Women with HIV Initiating ART in North America.
S. Coburn (2021)
White matter of perinatally HIV infected older youths shows low frequency fluctuations that may reflect glial cycling
M. Sarma (2021)
A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening
Christoph Gorgulla (2021)
Immunological and virological discordance among people living with HIV on highly active antiretroviral therapy in Tigray, Northern Ethiopia
Genet Gebrehiwet Hailu (2021)
Relationship of polypharmacy to HIV RNA suppression in people aged ≥ 50 years living with HIV
M. Murray (2021)
Intrapatient Development of Multi-Class Drug Resistance in an Individual Infected with HIV-1 CRF01_AE
Xiaorong Peng (2021)
Ingestible devices for long-term gastrointestinal residency: a review
Musharrat Mustaree Mau (2021)
Cardiovascular disease and prevention among people living with HIV in South Florida
F. Pyarali (2021)
HLA-mismatched allogeneic adoptive immune therapy in severely immunosuppressed AIDS patients
R. Xu (2021)
Prevalence of severe cardiovascular abnormalities amongst West African HIV-infected patients on antiretroviral therapy followed at a referral HIV centre
F. Ello (2021)
Breast Cancer and HIV: State of the Art and Practical Implications
Angioletta Lasagna (2021)
Potential drug-drug interactions of antiretrovirals and antimicrobials detected by three databases
P. Vivithanaporn (2021)
Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes.
Yenju Chu (2021)
Insights into the Interaction of SARS-COV-2 with ACE 2 Receptor
M. H. Najar (2021)
Green Tea (Camellia sinensis) Ameliorate Non-alcoholic Fatty Liver Disease Induced by Highly Active Antiretroviral Therapy
Dr.Tesaka Wondimnew (2021)
Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study
J. Gathe (2021)
Effect of Traditional Chinese Medicine Therapy on the Trend in CD4+ T-Cell Counts among Patients with HIV/AIDS Treated with Antiretroviral Therapy: A Retrospective Cohort Study
Dong-li Wang (2021)
Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy
S. Nozza (2021)
Infectious diseases of the upper gastrointestinal tract
N. Panarelli (2021)
CRISPR/Cas9-based genome engineering in HIV gene therapy
Xu Tang (2021)
Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength
E. Samuels (2021)
Prevalence of low bone mineral density among people living with HIV
T. Katzenstein (2021)
Association of HIV Infection and Antiretroviral Therapy With Arterial Stiffness: A Systematic Review and Meta-Analysis
Alvin Kuate Defo (2021)
Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research
F. Negri (2021)
Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015.
Thibaut Davy-Mendez (2021)
Types of Stroke Among People Living With HIV in the United States.
H. Crane (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar